Avanafil for male erectile dysfunction: a systematic review and meta-analysis

作者：Cui, Yuan-Shan; Li, Nan; Zong, Huan-Tao; Yan, Hui-Lei; Zhang, Yong^*

来源：Asian Journal of Andrology, 2014, 16(3): 472-477.

DOI：10.4103/1008-682X.123670

• avanafil
• erectile dysfunction
• meta-analysis
• randomized controlled trial

Avanafil, a potent new selective phosphodiesterase type 5 (PDE5) inhibitor, has been developed for the treatment of erectile dysED). We carried out a systematic review and meta-analysis to assess the efficacy and safety of this drug for the treatment of ED. A literature review was performed to identify all published randomized, double-blind, placebo-controlled trials of avanafil for the treatment of ED. The search included the following databases: MEDLINE, EMBASE and the Cochrane Controlled Trials Register. The reference lists of the retrieved studies were also investigated. Four publications, involving a total of 1381 patients, were used in the analysis, including four randomized controlled trials (RCTs) that compared avanafil with a placebo. Among the co-primary efficacy end points indicating that avanafil 100 mg was more effective than a placebo were successful vaginal penetration (SEP2) (the odds ratio (OR) =5.06, 95% confidence interval (CI) =3.29-7.78, P < 0.00001) and successful intercourse (SEP3) (OR = 3.99, 95% CI = 2.80-5.67, P < 0.00001). Men randomized to receive avanafil were less likely than those receiving the placebo to drop out due to an adverse event (AE) (OR = 1.48, 95% CI = 0.54-4.08, P = 0.44). Specific AEs with avanafil included headache and flushing, which were significantly less likely to occur with placebo. This meta-analysis indicates that avanafil 100 or 200 mg is an effective and well-tolerated treatment for ED. Compared with avanafil 100 mg, patients who take avanafil 200 mg are more likely to experience headaches.

• 出版日期2014-5
• 单位首都医科大学